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QuercetinAbstract Despite the current existence and availability of synthetic drugs for the treatment of dia-
betes mellitus (DM), these medications are neither cheap nor completely effective. Furthermore, the
long-term consumption of synthetic drugs may cause adverse effects, while those medications pro-
vided from natural sources are more affordable and have shown lesser adverse effects. The current
belief is that oxidative stress plays a substantial role in the pathogenesis of diabetes and its compli-
cations. The characteristics of DM as a multifactorial disease are related to a deﬁcit in the b-cells of
the pancreas that results in defective production and release of insulin. Antioxidant therapy can
protect b-cells from apoptosis and preserve their function. Therefore, the higher the antioxidant
effects a compound might have, the higher the positive effects in diabetes anticipated. Our idea
is that a combination of strong antioxidants might positively work in control of hyperglycemia
by activating the production and release of insulin to the blood. In this scenario, if the strongest
multi-herbal antioxidant complex called Setarud (IMOD) is combined with curcumin and quer-
cetin, then much stronger antioxidant activity with positive effects in the control of diabetes would
be produced. To prove the idea, this combination has to be pharmaceutically prepared and then its
safety and efﬁcacy must be examined in preclinical and clinical studies.
ª 2012 Tehran University of Medical Sciences. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Diabetes mellitus (DM) is the most common health problem of
the world in the current century. Nowadays more than
366 million people suffer from DM and 552 million are ex-lty of Pharmacy, and Pharmaceuti
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/j.jmhi.2012.12.002pected to be affected by diabetes by 2030 [1]. At the moment
there is no doubt that DM and its related complications are
associated with increased oxidative stress resulting from the
imbalance in the production of free radicals such as reactive
oxygen species (ROS) and the body’s antioxidant defence sys-cal Sciences Research Center, Tehran University of Medical Sciences,
ms.ac.ir (M. Abdollahi).
lished by Elsevier Ltd. Open access under CC BY-NC-ND license.
Curcumin 
Quercetin 
Figure 1 The chemical structure of curcumin and quercetin.
Adapted from free PubChem database provided by National
Center for Biotechnology Information, US National Library of
Medicine, 8600 Rockville Pike, Bethesda, MD 20894, USA.
26 O. Tabatabaei-Malazy et al.tem [2]. The ROSs have an important role in the aetiology of
diabetes and its complications [3]. The characteristics of DM
as a multifactorial disease are related to deﬁcit in b-cell mass
that leads to defects in production and release of insulin or
even improper action of insulin in various organs [4]. The anti-
oxidant therapy can preserve b-cell function by suppression of
b-cell apoptosis [3].
Even though, currently,many drugs have been used for treat-
ment of DM, many problems including the adverse effects are
associated with their continuous use. Moreover, the high cost
of these drugs is another issue in both developed and developing
countries [5,6] for patients who must use them for a long time.
Therefore, it seems very logical to think of alternative ap-
proaches in the management of diabetes. In the recent years, a
number of studies have been conducted on the use of herbal/nat-
ural products in diabetes. Although most of these studies re-
ported better antidiabetic effects with less side effects and
lower cost than synthetic drugs,most of themhave remained vir-
gin [7,8]. Our team’s studies in the last decade have shown that
most antidiabetic herbs have high antioxidant power and can
improve b-cell function and increase secretion of insulin from
Langerhans islets [6,8–10]. On the other hand, a tight link be-
tween oxidative stress, triggering of an inﬂammatory cascade
and pathogenesis of many chronic illnesses, particularly DM
[11], has been proved in the recent years. Thus, any compound
with good antioxidant and anti-inﬂammatory powers is funda-
mentally anticipated to show a good antidiabetic effect if used
properly [8]. Our recent studies and systematic reviews brought
up the idea that a combination of two or three or more strong
antioxidants can have an additive antidiabetic effect [8]. In the
present hypothesis, three natural compounds including Setarud
(IMOD), curcumin and quercetin are proposed for combina-
tion to result in amuch better antioxidant and antidiabetic drug.
Setarud isapatentedmulti-herbal complexcomposedofRosa
canina, Tanacetum vulgare, Urtica dioica, containing selenium
and urea treated by pulsed high frequency of an electromagnetic
ﬁeld [12]. Its effective antidiabetic activity has been shown in
autoimmune experimental diabetes and also on the viability
and function of islets based on in vitro studies [13,14]. Curcumin
as diferuloylmethane or 1,6-heptadiene-3,5-dione-1,7-bis (4-hy-
droxy-3-methoxyphenyl) is the active ingredient of the dietary
spice turmeric, from the plantCurcuma longa that has a long his-
tory of use as a traditional medicine in China and India [15]. The
chemical structure of curcumin is shown inFig. 1.Curcuminwas
ﬁrst introduced for its antibacterial activity, but later other
characteristics including hypolipidaemic, antidiabetic, anti-
inﬂammatory, antioxidant and anticancer activities were discov-
ered [16].Quercetin (3,30,40,5,7-pentahydroxyﬂavone) isapolyphe-
nolclassiﬁedasabioﬂavonoid,anditiswidelydistributedinvarious
plants, fruits and vegetables [17]. Its chemical structure is shown in
Fig.1.Beneﬁcialeffectsofpolyphenol-richfoodonreductionofthe
risk of cardiovascular diseases and cancer have been shown in
numerous prospective observational studies [18,19]. The antidia-
beticeffectofquercetinwithreductionofbloodglucose,promotion
of Langerhans islets’ regeneration and increasing insulin release
have been demonstrated both in vitro and in vivo [20–23].
Hypothesis
As mentioned above in addressing the current status in the
treatment of DM and the need for development of ‘newantidiabetic drugs’ with lower price and higher safety and efﬁ-
cacy, we aimed to hypothesise a ‘novel treatment of diabetes
by means of combined antioxidant compounds’. Although
the induction of possible additive or synergistic effects of phy-
tochemicals is not a new idea in general [24], speciﬁcally, no
idea has been raised on the combination of Setarud, curcumin
and quercetin in a speciﬁc disease such as diabetes. Using these
substances, one can assume that the new, generated compound
could be appropriate not only for ameliorating DM but also
for other diseases in which oxidative stress plays a role. Our
idea is to combine Setarud with curcumin and quercetin in
the best possible formulation to provide a lyophilised form
with sufﬁcient solubility. If lyophilised, there will be no or little
problem with the absorption of the combination form and
hopefully a better antidiabetic effect will be produced [16,25].
We also assumed that this compound can protect Langerhans
islets from free radical damage and improve islets’ function in
terms of better performance in the production and release of
insulin to control hyperglycemia.
Evaluation of the hypothesis
First, work should be carried out on this combination to pre-
pare a mixture with the best appearance, solubility and bio-
availability. Then, the antioxidant power of the combination
must be compared to each compound alone and to a standard.
efficacy of the proposed compounds
Completing preclinical phase studies
Safety assessment of each 
compound separately
Safety assessment of combined
compounds
In vivo and in vitro studies in animal model of 
type 2 DM in comparison to glibenclamide and 
metformin
Clinical trial (Phase 1) and finding maximum tolerated dose
Clinical trial (Phase 2-3)
Post-marketing surveillance
Collection of evidences  form literature for safety and 
Figure 2 Flowchart of practicing the hypothesis. Table 1 Direct and indirect molecular targets of curcumin.
Indirect molecular targets
–Transcription factors (16, 41)
–Enzymes (16, 41)
–Growth factors (16, 41)
–Receptors (16, 41)
–Cell-cycle regulatory proteins (16)
–Inﬂammatory molecules or mediators (16, 41)
–Protein kinases (16, 41)
–Drug resistance proteins (16)
–Adhesion molecules (16, 41)
–Cell survival proteins (16, 41)
–Chemokines and chemokine receptor (16)
–Invasion and angiogenesis biomarkers (16)
–Heat shock protein 70 (16, 41, 42)
–Metal ions, particularly iron and copper (42)
–Protein reductase (41)
Direct molecular targets
–Inﬂammatory molecules (16, 41)
–Cell survival proteins (16)
–Protein kinases (16, 41, 42)
–Protein reductases (16)
–Enzymes: histone deacetylase, glyoxalase I, xanthine oxidase,
proteasomes, HIV1 integrase, HIV1 protease, sacro/endoplasmic
reticulum Ca2+-ATPase, DNA methyltransferase 1 (16, 42)
–FtsZ protoﬁlaments (16)
–Carrier proteins (16)
–Metal ions (16)
A novel management of diabetes by means of strong antioxidants’ combination 27After that, an animal model of type 2 DM should be induced
by use of streptozocin (STZ) or alloxan and the compound
must be tested in these models in order to assess the potential
of the mixture in comparison to each compound alone and to
positive standards such as an oral hypoglycaemic agent (gli-
benclamide or metformin). The preference is to use both stan-
dards as they work by different mechanisms. A pilot study is
needed to reach the optimal dose of the combination com-
pound that has the highest efﬁcacy and safety. If preclinical
studies were successful and revealed worthwhile effects, then
clinical studies would be designed to start the clinical trial
phases of I–IV. The above-mentioned processes are shown as
a ﬂowchart in Fig. 2.
Discussion
In fact, Setarud has been already known for its direct and indi-
rect antioxidative effects through reduction of free radicals and
inhibition of inﬂammatory mediators [26–29]. The immuno-
modulatory effect of Setarud results in attenuation of tumour
necrosis factor-a (TNF-a), interleukin-1b (IL-1b), myeloperox-
idase and lipid peroxidation in many inﬂammatory conditions
including colitis, immune model of DM, islet cell transplanta-
tion and polycystic ovary syndrome [14,26,27,29,30]. Its anti-inﬂammatory effects are also shown in patients with oral Li-
chen planus, severe sepsis and acquired immunodeﬁciency syn-
drome (AIDS) [28,31,32]. The beneﬁcial anti-free-radical
activity and usefulness for treatment of oxidant-related dis-
eases are shown in the herbal constituents of Setarud [6]. In
addition, several studies have shown the separate antioxidative
activity of the main components of Setarud and other strong
antioxidants with the same components such as U. dioica,
Teucrium and selenium [33–36]. Fortunately, the safety of
Setarud has been proved in preclinical and clinical studies
[37,38]. Administration of 400 mg day1 Setarud for 3 months
showed an anti-inﬂammatory effect in patients with oral Li-
chen planus [28]. The maximum tolerated dose in intravenous
(IV) infusion of Setarud in HIV-infected patients was found to
be 10 ml day–1 [38].
Curcumin has direct and indirect molecular targets which
are shown in Table 1 [16,39], though the major targets are
key survival pathways regulated by nuclear factor jB (NF-
jB) and protein kinase B, as well as cytoprotective pathways
dependent on nuclear factor (erythroid-derived 2)-like 2
(Nrf2). Nrf2, also known as NFE2L2, is a transcription factor
that in humans is encoded by the NFE2L2 gene [39]. The pro-
inﬂammatory transcription factors NF-jB and signal trans-
ducer and activator of transcription 3 (STAT3) are major
mediatory effectors in inﬂammatory responses acting through
modulation of pro-inﬂammatory cytokines [16]. The inhibitory
effect of curcumin on pro-inﬂammatory cytokines and lipid
peroxidation has been already demonstrated [16]. Further-
more, its antioxidative and free-radical-scavenger activities
have been shown in rats [16]. Animal studies have shown its
beneﬁcial effects on various diseases including obesity, cancer
(especially colon cancer), wound healing, arthritis, psychiatric
disorders such as depression and Alzheimer’s, neurological,
28 O. Tabatabaei-Malazy et al.pulmonary and cardiovascular diseases [16,40,41]. Nearly 50
clinical trials have been conducted for assessing the potential
effects of curcumin in human diseases such as cancer, skin
and eye disorders and inﬂammatory conditions [16]. There
are strong evidences from animal studies regarding the positive
effects of curcumin in diabetic nephropathy, diabetic retinopa-
thy and insulin sensitivity [16,42]. All the evidences are in sup-
port of the idea that curcumin in adjuvant therapy of type 2
DM might be helpful through its antiangiogenic and antitoxic
activities [16,42]. The main problem of both Setarud and cur-
cumin is their low bioavailability, which calls for use of some
rather new techniques including employment of nanoparticles,
liposome encapsulation, micelles, phospholipid complexes,
structural analogues, etc. [16,43]. Combination of curcumin
with some antineoplastic drugs or with certain diet-derived
polyphenols such as epigallocatechin-3-gallate, piperine and
genistein has already demonstrated synergistic effects [44].
No animal or human studies have reported any toxic effect
even at very high doses of curcumin [45,46]. In healthy human
volunteers, no dose-limiting toxicities by a single dose of cur-
cumin ranging from 500 to 1200 mg day–1 was observed [46].
In another study, as little as 150 mg twice a day oral adminis-
tration of curcumin in humans showed anti-inﬂammatory ef-
fects [47]. 
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main etiology of diabetes and its complications.On the other hand, anti-free-radical activity and inhibitory
effects of quercetin on oxidation of bio-molecules have been
fairly shown in vitro and in vivo [48,49]. Exposure of isolated
islets of rat to certain ﬂavonoids, particularly quercetin, en-
hances insulin secretion by 44–70% [50]. Its effect on control-
ling the fasting and postprandial blood glucose is shown in
animal models of DM [51]. Other potential effects of quercetin
are iron chelation, preservation of nitric oxide, inhibition of
secretion of secretory phospholipase A2 (SPLA2) as stimulator
of tumour formation in colorectal, breast and prostate cancers,
anti-inﬂammatory effects, reduction of activity of transcription
factors and NF-jB, cardiac, hepatic and renal protection, pro-
tection of b-cells against oxidative damage, anti-lipid peroxida-
tion and antiproliferative effects, protection of red blood cell
membrane against haemolysis and acting as a chemopreventive
agent. Further, improvement of several diseases such as meta-
bolic syndrome, upper respiratory infection and rheumatoid
arthritis by quercetin has been reported [17,24,25,52]. In one
study, combination of curcumin and quercetin successfully re-
stored liver function and architecture, normalised kidney func-
tions and inhibited oxidative injury induced by paracetamol
[51]. Within the ﬂavonoid family, quercetin has the strongest
antioxidant and anti-inﬂammatory activities [52,53]. Depend-
ing on the type of glycoside in food source, the bioavailability 
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rud, curcumin and quercetin in management of oxidative stress as
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its half-life can increase by repeating intakes from 11 to 28 h.
However, contrary to Setarud and curcumin, quercetin has a
very good bioavailability, even better than other polyphenols.
Its safety has been already conﬁrmed in humans [25]. Querce-
tin was trialed in doses that ranged from 150 mg daily in sub-
jects with metabolic syndrome to 2000 mg day–1 in sarcoidosis
patients [25]. A schematic suggestion of the synergistic effects
of the proposed combination on oxidative stress as the main
aetiology of diabetes and its complications is shown in Fig. 3.
Conclusion
Through an alternative pharmacological approach for the con-
trol of diabetes, a combination of Setarud with curcumin and
quercetin might be an appropriate treatment.Overview Box
First question: What do we already know about the
subject?
Diabetes is one of the most common health problems
of the world. Most current antidiabetic drugs have side ef-
fects and are costly. Oxidative stress plays a major role in
the physiopathology of diabetes and results in damage to
Langerhans islets and decrease of insulin secretion. Any
compound with higher antioxidative activity could be an
effective antidiabetic drug.
Second question: What does your proposed theory add
to the current knowledge available, and what beneﬁts does
it have?
Our hypothesis introduces a novel natural mixture that
might improve function of pancreatic Langerhans islets
ending up with better management of diabetes mellitus.
Third question: Among numerous available studies, what
special further study is proposed for testing the idea?
First, the in vitro and in vivo studies in animal models
of type 2 diabetes should be tested to assess the efﬁcacy,
bioavailability, the optimal dose and the safety of the mix-
ture. Then, further trials should be continued in clinic to
complete phases 1–4 of drug approval.References
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